ProAgio Dose Expansion

Phase 1Small molecule

ProAgio Dose Expansion is one of 106 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

ProAgio Dose Expansion

PProDa BioTech, LLC

Phase 1

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Breast Cancer

NCT06460298

Q2 2028

Phase 1Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06182072

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting·PProDa BioTech, LLC·Phase 1·NCT06182072·46 enrolled

Pancreatic Cancer1 trial

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Active, not recruiting·PProDa BioTech, LLC·Phase 1·NCT05085548·58 enrolled

Breast Cancer1 trial

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Recruiting·PProDa BioTech, LLC·Phase 1/2·NCT06460298·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ProAgio Dose Expansion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ProAgio Dose Expansion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ProAgio Dose Expansion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ProDa BioTech, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PProDa BioTech, LLC

ProAgio Dose Expansion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Pancreatic Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News